Incretin-based drugs for the treatment of type 2 diabetes mellitus do not increase the risk of hospitalization for heart failure, according to the findings from a large, observational study. After previous reports of an association between this class of drug and the occurrence of adverse pancreatic events, concerns have also been raised about a potential increased risk of heart failure. Three randomized, placebo-controlled trials to examine this issue showed conflicting results.
In a retrospective study, investigators analysed multiple cohorts across three countries, for a total of almost 1.5 million patients with diabetes. Study cohorts were further defined according to the presence or absence of a history of heart failure. Subsequently, the researchers performed a nested case–control analysis in which cohort members hospitalized for heart failure were matched with event-free controls — up to 20 controls for each case were randomly selected according to sex, age, date of study entry, duration of treated diabetes, and duration of follow-up.
In both study cohorts, treatment with incretin-based drugs — which include dipeptidyl peptidase 4 inhibitors and glucagon-like peptide 1 mimetics — did not increase the risk of heart failure compared with combinations of oral antidiabetic drugs. Similar results were observed regardless of the class of incretin-based drug, duration of treatment, and history of myocardial infarction.
Despite the lack of information regarding the type of heart failure and the absence of long-standing diabetes in most cohort patients (who might have had a lower risk of heart failure) the investigators believe that they “had the statistical power to robustly assess this important drug safety issue” and conclude that “incretin-based drugs were not associated with an increased risk of hospitalization for heart failure”.
References
Filion, K. B. et al. A multicenter observational study of incretin-based drugs and heart failure. N. Engl. J. Med. 374, 1145–1154 (2016)
Rights and permissions
About this article
Cite this article
Ummarino, D. No increased risk of heart failure with incretin-based drugs. Nat Rev Cardiol 13, 248 (2016). https://doi.org/10.1038/nrcardio.2016.55
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2016.55